Form 4: Oncology Institute Director Gabriel Ling Acquires 40,000 Shares of Restricted Stock

Director Gabriel Ling of Oncology Institute, Inc. acquired 40,000 shares of restricted stock on November 22, 2024.

Summary

• Gabriel Ling, a director at Oncology Institute, Inc., acquired 40,000 shares of common stock on November 22, 2024.
• The shares were granted as restricted stock units at a price of $0.
• These restricted stock units will vest in full at the company's 2025 annual shareholder meeting, contingent on continued service with the company.
• Following this transaction, Mr. Ling's total holdings increased to 109,057 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock grants to directors, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future.
• The vesting schedule aligns the director's interests with the long-term performance of the company.

Risks

• The vesting of the restricted stock units is contingent on continued service, which could be a risk if the director leaves the company before the vesting date.

Future Outlook

The restricted stock units will vest in full at the 2025 annual shareholder meeting, subject to continued service with the company.

Industry Context

This type of stock grant is common practice for aligning the interests of company directors with the long-term success of the company.

Comparison to Industry Standards

• Stock grants to directors are a standard practice across the industry to incentivize performance and align interests with shareholders.
• The vesting schedule of the restricted stock units is typical, with vesting often tied to continued service and/or performance milestones.
• Companies like Amgen, Gilead, and Regeneron also use similar stock-based compensation for their directors.

Stakeholder Impact

• The stock grant to a director can be viewed positively by shareholders as it aligns management's interests with the company's long-term success.

Next Steps

• The restricted stock units will vest at the 2025 annual shareholder meeting, subject to continued service.

Key Dates

Keywords

restricted stock units, share acquisition, insider trading, beneficial ownership, director, Oncology Institute, TOI